Literature DB >> 24134199

Staging, prognostic factors and adjuvant therapy of intrahepatic cholangiocarcinoma after curative resection.

Tao Li1, Lun-Xiu Qin, Jian Zhou, Hui-Chuan Sun, Shuang-Jian Qiu, Qing-Hai Ye, Lu Wang, Zhao-You Tang, Jia Fan.   

Abstract

BACKGROUND & AIMS: Prognostic factors and adjuvant therapy of intrahepatic cholangiocarcinoma (ICC) after curative resection were not clear. We aim to analyse prognostic factors after curative resection and evaluate adjuvant therapy and survival based on the new staging system.
METHODS: A retrospective analysis of 283 patients who underwent surgical exploration for ICC was performed. Staging was performed according to the 7th edition AJCC staging manual. Univariate and multivariate analyses were used to evaluate independent prognostic factors.
RESULTS: The difference for OS at different TNM stages after R0 resection was significant (P < 0.001). Despite regional lymph node metastasis, tumour number and vascular invasion, serum GGT level was also an independent prognostic factor for OS of patients after R0 resection. The incidence of biliary and vascular invasion was significantly higher in high GGT group than in normal GGT group. Factors predictive of recurrence were multiple tumours and regional lymph node metastasis. After R0 resection, adjuvant TACE not only did not improve the OS of patients at TNM stage I (P = 0.508), but significantly promoted recurrence of these patients (P = 0.006). Only patients at TNM stage II, III and IV benefited from adjuvant TACE for longer survival, while the recurrence rates were not affected.
CONCLUSIONS: The new staging system can predict the survival of ICC patients after R0 resection. High GGT level may be suggestive of biliary and vascular invasion and was an independent risk factor for OS after R0 resection. Adjuvant TACE may be indicated only for patients at advanced stages for better survival.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  adjuvant therapy; intrahepatic cholangiocarcinoma; prognosis; recurrence; risk factors

Mesh:

Substances:

Year:  2013        PMID: 24134199     DOI: 10.1111/liv.12364

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  37 in total

1.  Hyperfibrinogenemia predicts poor prognosis in patients with advanced biliary tract cancer.

Authors:  Heming Li; Tong Zhao; Xuening Ji; Shanshan Liang; Zhe Wang; Yulong Yang; Jiajun Yin; Ruoyu Wang
Journal:  Tumour Biol       Date:  2015-10-09

2.  Implications of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic cholangiocarcinoma: A national cohort analysis.

Authors:  John R Bergquist; Tommy Ivanics; Curtis B Storlie; Ryan T Groeschl; May C Tee; Elizabeth B Habermann; Rory L Smoot; Michael L Kendrick; Michael B Farnell; Lewis R Roberts; Gregory J Gores; David M Nagorney; Mark J Truty
Journal:  J Surg Oncol       Date:  2016-07-20       Impact factor: 3.454

3.  The effect of adjuvant chemotherapy in patients with intrahepatic cholangiocarcinoma: a matched pair analysis.

Authors:  Nora Schweitzer; Tim Weber; Martha M Kirstein; Mareike Fischer; Anna-Maria Kratzel; Tanja Reineke-Plaaß; Frank Lehner; Michael P Manns; Arndt Vogel
Journal:  J Cancer Res Clin Oncol       Date:  2017-03-17       Impact factor: 4.553

4.  Glasgow Prognostic Score predicts prognosis of intrahepatic cholangiocarcinoma.

Authors:  Qun-Xiong Pan; Zi-Jian Su; Jian-Hua Zhang; Chong-Ren Wang; Shao-Ying Ke
Journal:  Mol Clin Oncol       Date:  2017-02-16

5.  Adjuvant Transarterial Chemoembolization Following Liver Resection for Intrahepatic Cholangiocarcinoma Based on Survival Risk Stratification.

Authors:  Jun Li; Qing Wang; Zhengqing Lei; Dong Wu; Anfeng Si; Kui Wang; Xuying Wan; Yizhou Wang; Zhenlin Yan; Yong Xia; Wan Yee Lau; Mengchao Wu; Feng Shen
Journal:  Oncologist       Date:  2015-05-08

Review 6.  Neoadjuvant and Adjuvant Therapy in Intrahepatic Cholangiocarcinoma.

Authors:  Xing Chen; Jinpeng Du; Jiwei Huang; Yong Zeng; Kefei Yuan
Journal:  J Clin Transl Hepatol       Date:  2022-01-04

Review 7.  Hepatitis B virus and hepatitis C virus play different prognostic roles in intrahepatic cholangiocarcinoma: A meta-analysis.

Authors:  Zheng Wang; Yuan-Yuan Sheng; Qiong-Zhu Dong; Lun-Xiu Qin
Journal:  World J Gastroenterol       Date:  2016-03-14       Impact factor: 5.742

8.  Impact of lymph node status in patients with intrahepatic cholangiocarcinoma treated by major hepatectomy: a review of the National Cancer Database.

Authors:  Zeljka Jutric; W Cory Johnston; Helena M Hoen; Pippa H Newell; Maria A Cassera; Chet W Hammill; Ronald F Wolf; Paul D Hansen
Journal:  HPB (Oxford)       Date:  2016-01       Impact factor: 3.647

9.  Postoperative adjuvant transarterial chemoembolization for intrahepatic cholangiocarcinoma patients with microvascular invasion: a propensity score analysis.

Authors:  Zhangjun Cheng; Zhengqing Lei; Xiaoling Jin; Qi Zhang; Anfeng Si; Pinghua Yang; Jiahua Zhou; Daniel Hartmann; Norbert Hüser; Feng Shen
Journal:  J Gastrointest Oncol       Date:  2021-04

Review 10.  The Role of Surgical Resection and Liver Transplantation for the Treatment of Intrahepatic Cholangiocarcinoma.

Authors:  Guergana Panayotova; Jarot Guerra; James V Guarrera; Keri E Lunsford
Journal:  J Clin Med       Date:  2021-05-30       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.